Repros Therapeutics, Inc. (RPRX)

[exwannabe]

Andro will likely go through existing T marketers becasue they already have the sales force and contacts in place. I don't think I would call this a "concern" of their's, just a natural progression.

It is possible that the top tier pharmas are less interested in andro because the T market does have a somewhat murky side to it (though this is just speculation by me).

I am a little skeptical about a deal shortly following Oct. 15th though. I doubt the FDA puts too much in firm writing at this point. If I was buying the rights, I would probably want to wait a few more months for a signed SPA (and despite the SPPI/GTCB fiasco, a SPA still is a formal agreement by the FDA).

Regardless, I think you are correct that this can all play out before a financing would be in play, and I can wait a little longer.

Cheers